STOCK TITAN
  1. Home
  2. Sec-filings
  3. KZIA
  4. [EFFECT] KAZIA THERAPEUTICS LTD SEC Filing

[EFFECT] KAZIA THERAPEUTICS LTD SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: December 22, 2025
Accession Number: 0001193125-25-326992
Submission Type: POS AM
CIK: 0001075880
Company Name: KAZIA THERAPEUTICS LTD
File Number: 333-276774

Source: View Original Filing on SEC EDGAR

Stock KZIA logo
Kazia Therapeuti

NASDAQ:KZIA

KZIA Rankings

#4849 Ranked by Market Cap
N/A Ranked by Dividends
#21 Top Loser

KZIA Latest News

Dec 22, 2025
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Dec 10, 2025
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
Dec 2, 2025
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
Nov 18, 2025
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
Oct 27, 2025
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

KZIA Latest SEC Filings

Dec 5, 2025
[6-K] KAZIA THERAPEUTICS LTD Current Report (Foreign Issuer)
Nov 18, 2025
[424B3] KAZIA THERAPEUTICS LTD Prospectus Filed Pursuant to Rule 424(b)(3)
Nov 18, 2025
[424B3] KAZIA THERAPEUTICS LTD Prospectus Filed Pursuant to Rule 424(b)(3)
Nov 18, 2025
[424B3] KAZIA THERAPEUTICS LTD Prospectus Filed Pursuant to Rule 424(b)(3)
Nov 18, 2025
[6-K] KAZIA THERAPEUTICS LTD Current Report (Foreign Issuer)

KZIA Stock Data

116.66M
10.58M
8.48%
8.91%
1.09%
Biotechnology
Pharmaceutical Preparations
Link
Australia
NEW SOUTH WALES 2113